Testing antiviral medicines for hepatitis B with normal liver blood tests
Part of Digestive system, Infections clinical trials.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hepatitis B confirmed by a positive surface antigen test
- You have had hepatitis B for more than 0.5 year
- You are between 18 and 65 years old
- Your ALT (a liver inflammation blood test) has been normal for at least 12 weeks
- You have not taken antiviral pills that work like nucleosides/nucleotides or interferon in the last 6 months
- You do not have certain other illnesses (like other active liver diseases or liver cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether switching to a newer antiviral medicine called tenofovir alafenamide (TAF, a pill for hepatitis B) is safe and works well for people who have had a liver transplant. The goal is to keep the liver healthy and reduce side effects compared to current treatment.
This trial studies what happens after stopping long-term hepatitis B antiviral medicine in people whose virus has stayed controlled. It also follows patients over time to see how well they remain stable and safe after stopping.
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
This trial tests whether a newer hepatitis B drug (tenofovir alafenamide) works as well and is as safe as the older drug (tenofovir disoproxil fumarate) for preventing hepatitis B from becoming active in people with blood cancers who are getting treatments that weaken the immune system.
Hear when a new Hepatitis B Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.